Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...
Insilico Medicine
Insilico Medicine’s AI-Discovered Drug INS018_055 Reaches Phase II Clinical Trial Milestone
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has announced that its lead pipeline candidate,...
Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement
China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman...
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...
Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi
China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...
Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery
Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...
Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...
Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics
China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...